3 results
The primary objective of this study is to evaluate the target engagement of AZD4831, MPO inhibitor by measuring MPO specific activity in plasma following ex vivo stimulation of fresh blood samples with zymosan, in patients with HFpEF. MPO is known…
Primary objectiveTo compare the event free survival per pathological review committee (PRC) of nivolumab plus BCG vs BCG alone in all randomized ParticipantsEFS, defined as the time from randomization until any of the following events: recurrence (…
This study aims to evaluate the effect of AZD4831 on functional improvement and reduction of symptoms in participants with heart failure with left ventricular ejection fraction > 40%. Additionally, the PK and overall safety profile of AZD4831…